Why Immunome (IMNM) Shares Climbed After Its Latest Update
Immunome (IMNM) just released third quarter results showing a wider loss, reporting a US$85.78 million net loss and a US$0.76 basic loss per share, along with new shelf registrations that raised questions about its capital structure.
Recent trading has been choppy. Immunome’s share price is at US$19.07 after a 1 month share price return of 8.48% and a 7 day move of 6.51%. However, the 3 month share price return has fallen 29.89% as investors weigh the wider losses, shelf registrations and progress around varegacestat. Over a longer horizon, total shareholder return is up 15.51% over 1 year and is about 14x over 3 years, which indicates that long term holders have still seen substantial gains even as short term momentum has cooled.
Scan how Immunome’s mix of wider losses, dilution risk and late stage oncology assets compares with other hand picked biotech players in the 19 high quality undiscovered gems list.
Immunome now combines a late stage oncology pipeline with a wider loss profile and new shelf capacity. After the recent pullback from three-year highs, is that mix already reflected in the US$19 share price or not yet?
Most Popular Narrative: 47% Undervalued
Immunome’s last close at $19.07 sits well below the analyst consensus Narrative fair value of $36.31, which uses a 7.46% discount rate and incorporates detailed revenue and earnings assumptions from multiple oncology programs. The analyst consensus Narrative on Simply Wall St ties that gap directly to how much value investors ascribe to varegacestat and the broader antibody drug conjugate and radioligand portfolio.
FDA acceptance of Immunome’s NDA for varegacestat in desmoid tumors with an April 28, 2027 PDUFA date sets up a potential first commercial product and a new revenue line that could shift the company’s earnings profile from primarily R&D expense to a mix of product sales and development spending.
See why 2 investors see Immunome as 47% undervalued.
Result: Fair Value of $36.31 (UNDERVALUED)
Still, the Immunome narrative could crack if varegacestat stumbles in FDA review or if slower desmoid tumor adoption drags out the path to meaningful product sales.
Find out about the key risks to this Immunome narrative.
Next Steps
With sentiment on Immunome split between wider losses and late stage potential, move quickly to inspect the details and pressure test the thesis for yourself using the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Immunome?
If Immunome has your attention, do not stop there. Broaden your watchlist now so you are not relying on a single biotech narrative.
- Target resilient balance sheets by scanning the list of solid balance sheet and fundamentals (24 results) to find companies that can better absorb shocks when conditions change.
- Zero in on potential value opportunities with the 32 high quality undervalued stocks to identify companies that combine quality fundamentals with lower implied expectations.
- Prioritise stability and income potential through the 6 dividend fortresses, which is focused on higher yielding businesses with the financial strength to support payouts.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com